David Lebowitz
Stock Analyst at Citigroup
(4.35)
# 379
Out of 5,117 analysts
119
Total ratings
60.92%
Success rate
14.58%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Buy | $69 → $84 | $79.93 | +5.09% | 14 | Sep 3, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $77 → $84 | $63.11 | +33.10% | 4 | Sep 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $56 → $48 | $26.38 | +81.96% | 2 | Aug 20, 2025 | |
| SDGR Schrödinger | Downgrades: Neutral | $35 → $20 | $18.31 | +9.23% | 10 | Aug 15, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $243 → $290 | $208.98 | +38.77% | 14 | Aug 8, 2025 | |
| INCY Incyte | Maintains: Buy | $88 → $103 | $100.11 | +2.89% | 6 | Jul 30, 2025 | |
| VKTX Viking Therapeutics | Maintains: Neutral | $31 → $38 | $37.18 | +2.21% | 2 | Jul 24, 2025 | |
| COGT Cogent Biosciences | Maintains: Buy | $15 → $22 | $38.88 | -43.42% | 4 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $58 → $67 | $75.80 | -11.61% | 5 | Jul 11, 2025 | |
| EXEL Exelixis | Maintains: Buy | $45 → $56 | $46.24 | +21.11% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $10 | $9.44 | +5.93% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $1.5 | $1.21 | +23.97% | 6 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $45 | $78.52 | -42.69% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $68 | $79.26 | -14.21% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $598.91 | -36.22% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $59.95 | +60.13% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $6.73 | +78.31% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $400.59 | -59.06% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $28.97 | +34.62% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $21.30 | -1.41% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $405 | $7.44 | +5,343.55% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $3.20 | +337.50% | 2 | Oct 12, 2021 |
Ionis Pharmaceuticals
Sep 3, 2025
Maintains: Buy
Price Target: $69 → $84
Current: $79.93
Upside: +5.09%
Cytokinetics
Sep 2, 2025
Maintains: Buy
Price Target: $77 → $84
Current: $63.11
Upside: +33.10%
Celldex Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $56 → $48
Current: $26.38
Upside: +81.96%
Schrödinger
Aug 15, 2025
Downgrades: Neutral
Price Target: $35 → $20
Current: $18.31
Upside: +9.23%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $243 → $290
Current: $208.98
Upside: +38.77%
Incyte
Jul 30, 2025
Maintains: Buy
Price Target: $88 → $103
Current: $100.11
Upside: +2.89%
Viking Therapeutics
Jul 24, 2025
Maintains: Neutral
Price Target: $31 → $38
Current: $37.18
Upside: +2.21%
Cogent Biosciences
Jul 18, 2025
Maintains: Buy
Price Target: $15 → $22
Current: $38.88
Upside: -43.42%
BridgeBio Pharma
Jul 11, 2025
Maintains: Buy
Price Target: $58 → $67
Current: $75.80
Upside: -11.61%
Exelixis
May 15, 2025
Maintains: Buy
Price Target: $45 → $56
Current: $46.24
Upside: +21.11%
May 9, 2025
Maintains: Neutral
Price Target: $14 → $10
Current: $9.44
Upside: +5.93%
Mar 4, 2025
Maintains: Neutral
Price Target: $4 → $1.5
Current: $1.21
Upside: +23.97%
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $78.52
Upside: -42.69%
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $79.26
Upside: -14.21%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $598.91
Upside: -36.22%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $59.95
Upside: +60.13%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $6.73
Upside: +78.31%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $400.59
Upside: -59.06%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $28.97
Upside: +34.62%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $21.30
Upside: -1.41%
Oct 12, 2021
Maintains: Overweight
Price Target: $435 → $405
Current: $7.44
Upside: +5,343.55%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $3.20
Upside: +337.50%